サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1616378

生体機能チップ（Organs-On-Chips）の世界市場規模：エンドユーザー別、用途別、タイプ別、地域別、範囲および予測

Global Organs-On-Chips Market Size By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Application (Physiological Model Development, Drug Discovery), By Type (Liver, Heart), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
生体機能チップ（Organs-On-Chips）の世界市場規模：エンドユーザー別、用途別、タイプ別、地域別、範囲および予測
出版日: 2024年10月31日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生体機能チップ（Organs-On-Chips）の市場規模と予測

Organs-On-Chips市場規模は、2024年に921億6,000万米ドルと評価され、2024年から2031年にかけてCAGR 10.56%で成長し、2031年には1,915億米ドルに達すると予測されています。Organs-on-Chipは、人間の臓器の構造と機能をミニチュアスケールで再現したマイクロ流体デバイスです。これらのチップには、臓器の生理学的環境を模倣するように配置された生きたヒト細胞が含まれており、研究者は臓器の機能、疾病メカニズム、薬物反応を制御された環境で研究することができます。従来の細胞培養や動物実験よりも正確なモデルを提供することで、生体機能チップ（Organs-On-Chips）はヒトの生物学に対する貴重な洞察を提供します。

生体機能チップ（Organs-On-Chips）の用途は多岐にわたり、様々な分野に影響を及ぼしています。主に医薬品開発や毒性試験で使用され、製薬会社は動物モデルだけに頼ることなく、新規化合物のヒト組織への影響を評価することができます。

さらに、これらのデバイスは疾患プロセスの研究にも使用でき、研究者はより生理学的に関連した状況で、がん、心血管疾患、神経変性疾患などの状態を調査することができます。

世界のOrgans-On-Chips市場力学

世界の生体機能チップ（Organs-On-Chips）市場を形成している主な市場力学

主な促進要因

微細加工の進歩：

微細加工技術の革新は、生体機能チップ（Organs-On-Chips）の設計と機能性を高め、その精度と応用性を向上させる。2024年2月に発表された米国国立標準技術研究所（NIST）の報告書によると、生物医学用途の微細加工研究への投資は2020年から2023年の間に35%増加しました。

個別化医療に対する需要の高まり：

個別化医療へのシフトは、薬物検査や疾患モデリングのための生体機能チップ（Organs-On-Chips）への関心を高め、オーダーメイドの治療ソリューションを提供します。米国食品医薬品局（FDA）は2024年1月、2023年の個別化医療の承認数が前年比28%増加したと報告しました。

規制上の支援：

医薬品開発や毒性試験のための規制機関による生体機能チップ（Organs-On-Chips）への認識の高まりが、製薬・バイオテクノロジー業界における採用を加速させています。例えば、欧州医薬品庁（EMA）は2024年1月、前臨床薬物試験における生体機能チップ（Organs-On-Chips）の使用に関する新ガイドラインを発表し、規制プロセスにおけるこの技術の受容が進んでいることを示しています。

主な課題

高い開発コスト：

生体機能チップ（Organs-On-Chips）に必要な複雑な製造工程と技術は、多額の研究開発費につながる可能性があります。

技術的限界：

現在のモデルでは、ヒト臓器の複雑さを完全に再現できない可能性があり、特定の研究分野における信頼性と適用性が制限されます。

規制上の課題：

薬物検査における生体機能チップ（Organs-On-Chips）の受容と標準化に向けて進化する規制状況をナビゲートすることは、普及のためのハードルとなります。

主要動向

AIおよび機械学習との統合：

AI技術の導入により、データ分析と予測モデリングが強化され、医薬品検査や疾患研究における生体機能チップ（Organs-On-Chips）・システムの精度が向上します。2024年1月に発表された米国立衛生研究所（NIH）の報告書によると、生体機能チップ（Organs-On-Chips）・システムと組み合わせたAIの使用は、2021年から2023年の間に58%増加しました。

多臓器モデルの拡大：

多臓器チップへの関心が高まることで、より複雑な相互作用が可能になり、ヒトの生理学をよりよくシミュレーションできるため、薬剤の有効性と安全性の評価が進みます。例えば、2024年1月には、TissUse GmbH社が「Human-on-a-Chip」プラットフォームを発表し、1つのマイクロ流体デバイスで最大10種類の臓器モデルを接続できるようになった。

疾患モデルへの注力：

疾患特異的モデルに対する需要の高まりが、生体機能チップ（Organs-On-Chips）における技術革新を促進し、がん、心血管疾患、神経変性疾患などの疾患に関する研究を促進します。例えば、2024年2月、Emulate, Inc.はアルツハイマー病協会との共同開発を発表し、神経変性疾患のモデルとして特別に設計された「ブレインチップ」を開発しました。

目次

第1章 世界の生体機能チップ（Organs-On-Chips）市場のイントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • 検証
  • プライマリーインタビュー
  • データソース一覧
  • 市場の魅力

第4章 世界の生体機能チップ（Organs-On-Chips）市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 生体機能チップ（Organs-On-Chips）の世界市場：タイプ別

  • 心臓オンチップ
  • ヒトオンチップ
  • 腸オンチップ
  • 腎臓オンチップ
  • オンチップ肝臓
  • 肺オンチップ

第6章 生体機能チップ（Organs-On-Chips）世界市場：用途別

  • 創薬
  • トキシコロジー研究v
  • 生理モデル
  • その他の用途

第7章 生体機能チップ（Organs-On-Chips）世界市場：エンドユーザー別

  • 製薬およびバイオテクノロジー企業
  • 学術機関
  • 研究機関

第8章 生体機能チップ（Organs-On-Chips）の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第9章 世界の生体機能チップ（Organs-On-Chips）市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略
  • ACEマトリックス

第10章 企業プロファイル

  • BiomimX SRL
  • Elveflow
  • Hesperos
  • Altis Biosystems
  • Nortis Inc.
  • AxoSim
  • Bi/ond
  • InSphero
  • Emulate Inc.
  • Allevi Inc.
  • MIMETAS BV
  • Netri
  • Valo Health（Tara Biosystems Inc.）
  • TissUse GmbH

第11章 主な発展

  • 製品の上市／開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連調査
目次
Product Code: 4897

Organs-On-Chips Market Size And Forecast

Organs-On-Chips Market size was valued at USD 92.16 Billion in 2024 and is projected to reach USD 191.5 Billion by 2031, growing at a CAGR of 10.56% from 2024 to 2031. Organs-on-chips are microfluidic devices that replicate the structure and function of human organs at a miniature scale. These chips contain living human cells arranged in a way that mimics the physiological environment of the organs they represent, enabling researchers to study organ functions, disease mechanisms, and drug responses in a controlled setting. By providing a more accurate model than traditional cell culture or animal testing, organs-on-chips offer valuable insights into human biology.

The applications of organs-on-chips are diverse and impactful across various fields. They are primarily used in drug development and toxicity testing, allowing pharmaceutical companies to assess the effects of new compounds on human tissues without relying solely on animal models.

Additionally, these devices can be used to study disease processes, enabling researchers to investigate conditions like cancer, cardiovascular diseases, and neurodegenerative disorders in a more physiologically relevant context.

Global Organs-On-Chips Market Dynamics

The key market dynamics that are shaping the global organs-on-chips market include:

Key Drivers

Advancements in Microfabrication:

Innovations in microfabrication technologies enhance the design and functionality of organs-on-chips, improving their accuracy and applicability. According to a report by the National Institute of Standards and Technology (NIST) published in February 2024, investments in microfabrication research for biomedical applications increased by 35% between 2020 and 2023.

Rising Demand for Personalized Medicine:

The shift towards personalized medicine fuels interest in organs-on-chips for drug testing and disease modeling, providing tailored therapeutic solutions. The U.S. Food and Drug Administration (FDA) reported in January 2024 that the number of personalized medicine approvals increased by 28% in 2023 compared to the previous year.

Regulatory Support:

Increasing recognition of organs-on-chips by regulatory bodies for drug development and toxicity testing accelerates adoption in pharmaceutical and biotech industries. For instance, in January 2024, the European Medicines Agency (EMA) released new guidelines for the use of organs-on-chips in preclinical drug testing, signaling growing acceptance of this technology in regulatory processes.

Key Challenges:

High Development Costs:

The complex manufacturing processes and technology required for organs-on-chips can lead to significant research and development expenses.

Technical Limitations:

Current models may not fully replicate the complexity of human organs, limiting their reliability and applicability in certain research areas.

Regulatory Challenges:

Navigating the evolving regulatory landscape for acceptance and standardization of organs-on-chips in drug testing poses hurdles for widespread adoption.

Key Trends

Integration with AI and Machine Learning:

The incorporation of AI technologies enhances data analysis and predictive modeling, improving the accuracy of organ-on-chip systems in drug testing and disease research. According to a report by the National Institutes of Health (NIH) published in January 2024, the use of AI in conjunction with organ-on-chip systems increased by 58% between 2021 and 2023.

Expansion of Multi-Organ Models:

Increasing interest in multi-organ chips allows for more complex interactions and better simulation of human physiology, advancing drug efficacy and safety assessments. For instance, in January 2024, TissUse GmbH unveiled their "Human-on-a-Chip" platform, capable of connecting up to ten different organ models in a single microfluidic device.

Focus on Disease Modeling:

Growing demand for disease-specific models drives innovation in organs-on-chips, facilitating research on conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. For instance, in February 2024, Emulate, Inc. announced a collaboration with the Alzheimer's Association to develop a "Brain-Chip" specifically designed to model neurodegenerative disorders.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Organs-On-Chips Market Regional Analysis

Here is a more detailed regional analysis of the global organs-on-chips market:

North America

North America is dominating the organs-on-Chips market, driven by substantial investments in research and development, a robust biotechnology sector, and supportive regulatory frameworks. The U.S. National Institutes of Health (NIH) reported allocating USD 89 Million in fiscal year 2023 to support research on microphysiological systems, including organs-on-chips, highlighting the region's commitment to advancing this technology. This significant funding has accelerated the development and adoption of organs-on-chips across pharmaceutical companies, academic institutions, and research organizations in North America.

The region's dominance is further solidified by the presence of leading market players and a growing emphasis on reducing animal testing in drug development. According to the U.S. Food and Drug Administration (FDA), the average cost to develop a new drug exceeds USD 2.6 Billion, with a significant portion attributed to preclinical testing. Organs-on-chips technology offers a promising solution to reduce these costs and improve the efficiency of drug discovery processes, driving its adoption across the pharmaceutical industry in North America.

Recent developments in the market have seen key players introducing innovative solutions and expanding their product offerings. In February 2024, Emulate Inc. announced the launch of a new multi-organ chip platform capable of simulating complex organ interactions, aimed at enhancing drug toxicity studies. Additionally, CN Bio Innovations reported in December 2023 a collaborative agreement with a major U.S. pharmaceutical company to develop custom organ-on-chip models for respiratory disease research, demonstrating the growing industry adoption of this technology in North America.

Asia Pacific

The Asia Pacific region is experiencing rapid growth in the organs-on-chips market, driven by increasing investment in life sciences research, rising demand for personalized medicine, and government initiatives to promote innovative healthcare technologies.

According to the Japan Agency for Medical Research and Development (AMED), the country invested approximately 146 billion yen (USD 1.3 Billion) in fiscal year 2022 for medical research and development, with a significant portion allocated to advanced biotechnologies like organs-on-chips. This substantial funding has catalyzed research activities and collaborations between academic institutions and industry players, fostering the adoption of organs-on-chips technology across the region.

The market's growth is further propelled by the region's large and diverse patient population, which presents unique opportunities for drug discovery and personalized medicine applications. China's National Medical Products Administration (NMPA) reported in 2023 that the country had over 5,000 new drug applications under review, highlighting the immense potential for organs-on-chips technology to streamline the drug development process. This has led to increased collaboration between local pharmaceutical companies and organs-on-chips developers to create more efficient and cost-effective drug screening methods.

Global Organs-On-Chips Market: Segmentation Analysis

The Global Organs-On-Chips Market is segmented on the basis of End-User, Application, Type, And Geography.

Organs-On-Chips Market, By End-User

  • Pharmaceutical and biotechnology companies
  • Academic
  • Research institutes

Based on the End-User, the Global Organs-On-Chips Market is segmented into Pharmaceutical and biotechnology companies, Academic, Research institutes. In the organs-on-chips market, pharmaceutical and biotechnology companies are the dominant end users, leveraging these technologies to enhance drug development processes and improve safety assessments. Meanwhile, the academic segment is experiencing rapid growth, fueled by increasing research initiatives and funding aimed at understanding complex biological systems. This trend underscores the importance of innovative educational tools in advancing scientific research and fostering collaboration between academia and industry.

Organs-On-Chips Market, By Application

  • Drug Discovery
  • Toxicology Research
  • Physiological Model
  • Others

Based on the Application, the Global Organs-On-Chips Market is segmented into Drug Discovery, Toxicology Research, Physiological Model, and Others. In the organs-on-chips market, the drug discovery segment is currently the dominant application, as it plays a crucial role in streamlining the drug development process and improving success rates. However, the toxicology research segment is experiencing rapid growth, driven by the increasing need for safer and more effective testing methods that reduce reliance on animal models. This shift reflects a broader trend toward regulatory compliance and ethical considerations in biomedical research.

Organs-On-Chips Market, By Type

  • Heart on chip
  • Human on chip
  • Intestine on chip
  • Kidney on chip
  • Liver on chip
  • Lung on chip

Based on Type, the Global Organs-On-Chips Market is segmented into Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, and Lung on chip. In the organs-on-chips market, the liver on chip segment is currently dominating, driven by its critical role in drug metabolism and toxicity testing. However, the heart on chip segment is rapidly growing, fueled by increasing interest in cardiovascular disease research and personalized medicine applications. This trend highlights the rising demand for innovative models that can replicate complex organ functions for more accurate drug testing and development.

Organs-On-Chips Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Organs-On-Chips Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the organs-on-chips market, North America currently dominates due to its robust biotechnology sector and significant investments in research and development. However, the Asia Pacific region is emerging rapidly, driven by increasing government support for advanced biomedical technologies and a growing emphasis on personalized medicine. This shift indicates a strong potential for growth in Asia Pacific as it invests in innovative healthcare solutions.

Key Players

  • The "Global Organs-On-Chips Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • BiomimX SRL, Elveflow, Hesperos, Altis Biosystems, Nortis, Inc., AxoSim, Bi/ond, InSphero, Emulate, Inc., Allevi, Inc., MIMETAS BV, Netri, Valo Health (Tara Biosystems, Inc.), TissUse GmbH., MesoBiotech, Chiron, Cherry Biotech, 4Dcell, BioIVT, AlveoliX, BEOnchip, Tissue Dynamics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Organs-On-Chips Market Key Developments

  • In August 2023, Emulate, Inc. announced the launch of its next-generation organ-on-chip platform, which offers enhanced predictive capabilities for drug response and toxicity testing, promising to accelerate drug development timelines.
  • In July 2023, researchers at MIT unveiled a novel multi-organ chip system that simulates human organ interactions more accurately, paving the way for improved disease modeling and personalized medicine applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ORGANS-ON-CHIPS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources
  • 3.5 Market attractiveness

4 GLOBAL ORGANS-ON-CHIPS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ORGANS-ON-CHIPS MARKET, BY TYPE

  • 5.1 Heart on chip
  • 5.2 Human on chip
  • 5.3 Intestine on chip
  • 5.4 Kidney on chip
  • 5.5 Liver on chip
  • 5.6 Lung on chip

6 GLOBAL ORGANS-ON-CHIPS MARKET, BY APPLICATION

  • 6.1 Drug discovery
  • 6.2 Toxicology research
  • 6.3 Physiological Model
  • 6.4 Other applications

7 GLOBAL ORGANS-ON-CHIPS MARKET, BY END USER

  • 7.1 Pharmaceutical and biotechnology companies
  • 7.2 Academic
  • 7.3 Research institutes

8 GLOBAL ORGANS-ON-CHIPS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL ORGANS-ON-CHIPS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 ACE Matrix

10 COMPANY PROFILES

  • 10.1 BiomimX SRL
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Elveflow
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Hesperos
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Altis Biosystems
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Nortis Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 AxoSim
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Development
  • 10.7 Bi/ond
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 InSphero
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Development
  • 10.9 Emulate Inc.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
  • 10.10 Allevi Inc.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
  • 10.11 MIMETAS BV
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
  • 10.12 Netri
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
  • 10.13 Valo Health (Tara Biosystems Inc.)
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
  • 10.14 TissUse GmbH
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research